InvestorsHub Logo
icon url

F1ash

09/02/17 9:08 AM

#118278 RE: Amatuer17 #118276

It looks to me like A2-73 would belong under "symptom improvement" (Treat)



https://reverserett.org/wp-content/themes/RSRT/assets/img/map.svg



https://reverserett.org/cure/


" Taken together, these behavioral paradigms measure different aspects of muscular coordinaton, balance, motor learning and muscular strengths, some of the core deficits observed in Rett syndrome"

" Administra,on of ANAVEX 2-73 results in both significant and dose related improvements in an array of behavioral paradigms in the MECP2 HET Rett syndrome disease model"

http://www.anavex.com/my_uploads/Assessment-of-Anavex-2-73-in-a-MECP2-Rett-Syndrome-Mouse-Model.pdf



icon url

samk

09/02/17 10:37 AM

#118286 RE: Amatuer17 #118276

Since Rett Syndrom Foundation is financially supporting AVXL trials, it is logically expected, that RSF will encourage parents to participate in this particular trial. How many patients do we need?
icon url

Steady_T

09/02/17 8:31 PM

#118326 RE: Amatuer17 #118276

The theory of restored homeostasis addresses Rett by postulating that the ER is misfolding proteins due to insufficient ATP and perhaps other molecules produced by the mitochondria supplying the ER.

By reestablishing the connection between the mitochondria and the ER the misfolded and therefore ineffective proteins will no longer be produced.

The result is the ER is now producing effective proteins. If it is this faulty connection mechanism that results in insufficient MeCP2 protein then 2-73 becomes a plausible mechanism for creating the proper amount.

Obviously there are multiple other links in the chain that leads to insufficient MeCP2 protein levels that might not be addressed by 2-73.

Is MeCP2 prodcued in the ER? I do not know.